Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $12000.0.

  • Anaptysbio's Capital Expenditures fell 6571.43% to $12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $349000.0, marking a year-over-year decrease of 693.33%. This contributed to the annual value of $358000.0 for FY2024, which is 5563.82% down from last year.
  • Anaptysbio's Capital Expenditures amounted to $12000.0 in Q3 2025, which was down 6571.43% from $39000.0 recorded in Q2 2025.
  • Anaptysbio's 5-year Capital Expenditures high stood at $863000.0 for Q2 2021, and its period low was $12000.0 during Q3 2025.
  • Its 5-year average for Capital Expenditures is $156578.9, with a median of $78000.0 in 2022.
  • Per our database at Business Quant, Anaptysbio's Capital Expenditures tumbled by 9549.84% in 2021 and then skyrocketed by 115000.0% in 2022.
  • Anaptysbio's Capital Expenditures (Quarter) stood at $14000.0 in 2021, then soared by 1150.0% to $175000.0 in 2022, then skyrocketed by 60.0% to $280000.0 in 2023, then decreased by 6.07% to $263000.0 in 2024, then crashed by 95.44% to $12000.0 in 2025.
  • Its Capital Expenditures stands at $12000.0 for Q3 2025, versus $39000.0 for Q2 2025 and $35000.0 for Q1 2025.